Leaflet LENALIDOMIDA ALVOGEN 5mg capsules


Indicated for: multiple myeloma

Substance: lenalidomide (immunomodulator)

ATC: L04AX04 (Antineoplastic and immunomodulating agents | Immunosuppressants | Other immunosuppressants)

Lenalidomide is a medication used for the treatment of multiple myeloma, myelodysplastic syndromes, and other hematologic conditions. It works by modulating the immune system and inhibiting tumor cell growth.

The medication is taken orally, usually once daily, as part of a treatment cycle prescribed by a doctor. Regular monitoring of hematologic function is important, and precautions must be taken to avoid pregnancy.

Side effects may include fatigue, anemia, neutropenia, or skin rashes. In rare cases, deep vein thrombosis or severe allergic reactions may occur.

Lenalidomide is not recommended for pregnant women or those planning to become pregnant, as well as patients with hypersensitivity to this medication.

General data about LENALIDOMIDA ALVOGEN 5mg

  • Substance: lenalidomide
  • Date of last drug list: 01-05-2026
  • Commercial code: W64955002
  • Concentration: 5mg
  • Pharmaceutical form: capsules
  • Quantity: 21
  • Product type: generic
  • Price: 11541.27 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: PHARMADOX HEALTHCARE LTD. - MALTA
  • Holder: ALVOGEN MALTA OPERATIONS (ROW) LTD. - MALTA
  • Number: 10936/2018/02
  • Shelf life: 3 years

Concentrations available for lenalidomide

  • 10mg
  • 15mg
  • 2.5mg
  • 20mg
  • 25mg
  • 5mg
  • 7.5mg

Compensation lists for LENALIDOMIDA ALVOGEN 5mg Alvogen

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

11541.27 RON

1378.20 RON

10163.07 RON